Regeneron Pharmaceuticals' Tax Provisions rose 99.02% to $303.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.1 million, marking a year-over-year increase of 80.09%. This contributed to the annual value of $367.3 million for FY2024, which is 49.49% up from last year.
As of Q3 2025, Regeneron Pharmaceuticals' Tax Provisions stood at $303.3 million, which was up 138.63% from $127.1 million recorded in Q2 2025.
Regeneron Pharmaceuticals' 5-year Tax Provisions high stood at $653.9 million for Q2 2021, and its period low was -$21.3 million during Q1 2024.
For the 3-year period, Regeneron Pharmaceuticals' Tax Provisions averaged around $103.6 million, with its median value being $103.0 million (2023).
As far as peak fluctuations go, Regeneron Pharmaceuticals' Tax Provisions skyrocketed by 2,927.31% in 2021, and later plummeted by 152.99% in 2024.
Regeneron Pharmaceuticals' Tax Provisions (Quarterly) stood at $274.4 million in 2021, then plummeted by 53.50% to $127.6 million in 2022, then slumped by 109.40% to -$12.0 million in 2023, then surged by 436.67% to $40.4 million in 2024, then surged by 99.02% to $303.3 million in 2025.
Its Tax Provisions was $303.3 million in Q3 2025, compared to $127.1 million in Q2 2025 and $96.3 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value